Founder of Calliditas Therapeutics AB, Bengt Åke Julander is a businessperson who has been the head of 7 different companies and is Chairman at Knil AB and
Börsnotering av Calliditas Therapeutics AB på Nasdaq Stockholm år 2018. Bengt Julander (direkt och genom bolag) 24,7 %, Zaragatero Ltd 9,2 %.
Aktieinnehav: 5 840 172 av serie B (genom bolag). Calliditas Therapeutics AB hette tidigare Pharmalink AB. Industrifonden, Investinor AS and Bengt Julander (exklusive ägandet via Linc AB) vills sälja för 90 Mkr. Den amerikanska specialistinvesteraren BVF Partners har uttryckt sitt intresse att investera 12 miljoner dollar i bolaget. Calliditas Therapeutics is a smaller company with a market capitalization of kr2.9b, The second largest shareholder with 13%, is Investinor AS, followed by Bengt Julander, with an ownership of 9.5%. Bengt Julander also happens to hold the title of Member of the Board of Directors. Founder of Calliditas Therapeutics AB, Bengt Åke Julander is a businessperson who has been the head of 7 different companies and is Chairman at Knil AB and Chief Executive Officer & Director at Linc Calliditas Therapeutics AB (publ) (”Calliditas” eller ”Bolaget”), ett specialistläkemedelsbolag inriktat på utveckling av högkvalitativa läkemedel i nischindikationer har, i enlighet med vad som offentliggjordes i Bolagets pressmeddelande den 2 juli 2019, beslutat om och genomfört en nyemission av 3 505 291 aktier, till en teckningskurs om 60 kronor per aktie (”Nyemissionen”). 2019-04-04 00:24 Hälsovårdsinvesteraren Bengt Julander 01:34 Bengt Julanders största noterade aktieinnehav 03:17 Gemensamma nämnare för bolagen i Bengt Julanders portfö På allabolag.se hittar du företagsinformation om bengt julander.
2019-04-04 00:24 Hälsovårdsinvesteraren Bengt Julander 01:34 Bengt Julanders största noterade aktieinnehav 03:17 Gemensamma nämnare för bolagen i Bengt Julanders portfö På allabolag.se hittar du företagsinformation om bengt julander. allabolag.se ger alla tillgång till bokslut, befattningshavare, kreditupplysningar, adresser och annan företagsinformation. Bengt Julander. Född: 1953 Titel: Ledamot sedan 2017. Utbildning: Apotekare och har arbetat i läkemedelsindustrin sedan 1978.
STOCKHOLM (Nyhetsbyrån Direkt) Hälsovårdsinvesteraren Bengt Julanders investeringsbolag Linc har köpt fler aktier i Calliditas och därmed ökat till nästan 5 … Ownership as of December 30, 2020 Number of shares Per cent BVF Partners LP 6,331,562* 12.68%* Stiftelsen Industrifonden 5,772,995 11.56% Bengt Julander/Linc Ägande per 30 december 2020 Antal aktier Procent BVF Partners LP 6 331 562* 12,68%* Stiftelsen Industrifonden 5 772 995 11,56% Bengt Julander/Linc 4 Calliditas betalar cirka 56 Mkr i emissionskostnader, motsvarande 8,6 procent av erbjudandet.
Bengt Julander also happens to hold the title of Member of the Board of Directors. A deeper analysis brings to light the fact that 55% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.
Calliditas is seeking accelerated Bengt Åke Julander is Chief Executive Officer & Director at Linc Invest AB. View Bengt Åke Julander’s professional profile on Relationship Science, the database of decision makers. Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company.
Ownership as of December 30, 2020 Number of shares Per cent BVF Partners LP 6,331,562* 12.68%* Stiftelsen Industrifonden 5,772,995 11.56% Bengt Julander/Linc
Lars.
Bengt Julander säljer inga aktier i Bolaget från Linc AB, där majoriteten av innehavet innehas, och har uttryckt sin intention att vara en fortsatt långsiktig ägare i Bolaget. Industrifonden, Investinor och Mikael Bender (f.d.
Euroscore cardiac surgery
1y.
Calliditas Therapeutics AB hette tidigare Pharmalink AB. Industrifonden, Investinor AS and Bengt Julander (exklusive ägandet via Linc AB) vills sälja för 90 Mkr. Den amerikanska specialistinvesteraren BVF Partners har uttryckt sitt intresse att investera 12 miljoner dollar i bolaget. Calliditas Therapeutics is a smaller company with a market capitalization of kr2.9b, The second largest shareholder with 13%, is Investinor AS, followed by Bengt Julander, with an ownership of 9.5%.
Issn no of materials today proceedings
torakan dojo
astrazeneca logo transparent
miljoklass 2021
voddler log in
Calliditas Therapeutics AB ADR. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden. Partner Content.
Born 1956. Board member since 2009. Education: PhD in Genetics from the University of Umeå.. Experience: Lennart Hansson has broad experience from leading positions within pharmaceutical development and business development in both biotech and pharma companies such as KabiGen AB, Symbicom AB, AstraZeneca, Biovitrum AB and as CEO of Arexis AB. Calliditas Therapeutics AB (publ) (”Calliditas” or the ”Company”), a specialty pharmaceutical company focused on the development of high quality pharmaceutical products within niche indications, today announced its intention to carry out a directed share issue of approximately SEK 200 million (the “Issue”) to Swedish and international institutional investors. Founder of Calliditas Therapeutics AB, Bengt Åke Julander is a businessperson who has been the head of 7 different companies and is Chairman at Knil AB and Chief Executive Officer & Director at Linc Invest AB. About Calliditas Therapeutics AB - ADR The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.